Dr. Mark Lambrecht is Global Head of Health Care and Life Sciences Advisory at SAS. He and his team operate on the intersection of research, information science and analytical cloud technology to solve advanced analytical and AI challenges at hospitals, pharmaceutical manufacturers and various health care organisations. Prior to joining SAS, he worked in the pharmaceutical industry and obtained a Masters and PhD in Applied Bioscience Engineering, Cell- and Gene Technology at the University of Leuven (Belgium) and conducted Postdoctoral Research at Stanford University (USA).
Clinical trials are the engine behind every new treatment we see – from life-saving cancer drugs to vaccines that help us fight global pandemics. But behind the scenes, running these trials involves juggling massive amounts of complex, sensitive data. For pharmaceutical companies, outdated technology systems can slow everything down, delaying
Heather Cartwright, General Manager of Microsoft Health, joined me to contemplate the new horizons in healthcare made possible by SAS and Microsoft’s new strategic partnership. The four walls of the doctor’s office are disappearing. Following decades of planning for hypotheticals, this year health care organizations were compelled to make good on the promise of digital transformation. Meeting the
In the early days and weeks of any widespread global health concern, particularly in a fast-moving outbreak like the coronavirus, there are many unknowns. Data visualization can be a good starting point to understand trends and piece data points together into a meaningful story. The ability to visualize the spread
What would happen if we could ask any type of scientific or clinical question about patients, and then go out and find the data to answer our questions? With "real-world data," we can do just that. Real-world data is all medicinal product data that comes from real-life patients. In contrast,
